NCT01665794: Phase 1/2: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With RRMM
NCT01677858: Phase 1/2: Weekly Carfilzomib + Dex for Progressive Multiple Myeloma (CHAMPION 1)
NCT01723020: A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
NCT01729091: Phase 2: Umbilical Cord Blood-Derived NK Cells, Elotuzumab, Len, Melphalan f/b ASCT
NCT01568866: Phase 3 - Carfilzomib and Dex Vs Bortezomib & Dex for Relapsed Myeloma (ENDEAVOR)
NCT01592370: Phase 1/2: Safety and Effectiveness of Nivolumab and Daratumumab in Multiple Myeloma
NCT01734928: Phase 3 - Safety/Efficacy of Pom Bortezomib and Low-dose Dex in relapsed MM (OPTIMISMM)
NCT01712789: Phase 3 - Pomalidomide + Dex (Low Dose) Refractory or Relapsed Multiple Myeloma STRATUS
NCT01464034: Phase 1/2 - Carfilzomib, Pomalidomide With Dexamethasone in Patients With RRMM
NCT01410500: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With RRMM Myeloma
NCT01311687: Phase 3 - Efficacy & Safety of Pomalidomide & Low dose dex Vs High-Dose Dex - NIMBUS
NCT01421524: Phase 1: Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness
NCT01415882: Phase 2: Ixazomib Citrate in Relapsed Multiple Myeloma, Not Refractory to Bortezomib
NCT01081028: Connect® MM- The Multiple Myeloma Disease Registry
NCT01239797: Phase 3: Lenalidomide and Dexamethasone With or Without Elotuzumab RRMM (ELOQUENT - 2)
GMMG phase III trial ReLApsE Salvage autologous transplant and lenalidomide maintenance vs. len-Dex
NCT01155583: Phase 1/2: Low-Dose Azacitidine, Lenalidomide & Low-Dose Dexamethasone in RRMM Myeloma
NCT01080391: Comparing Carfilzomib, Lenalidomide & Dex (CRd) vs Lenalidomide and Dex (Rd) - ASPIRE
NCT00833833: Phase 1/2: MTD, Safety, and Efficacy of Pomalidomide (CC-4047) +/- Dexamethasone RRMM